(Q40675012)

22 September 2017

title

Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers (English)

1 reference

22 September 2017

0 references

Giuseppe Remuzzi

14

0 references

Sheldon W. Tobe

15

object named as

Sheldon Tobe

1 reference

22 September 2017

10

Dalane W Kitzman

1 reference

22 September 2017

Bauke Schievink

1

1 reference

22 September 2017

Dick de Zeeuw

2

1 reference

22 September 2017

Paul A Smink

3

1 reference

22 September 2017

Dennis Andress

4

1 reference

22 September 2017

John J Brennan

5

1 reference

22 September 2017

Blai Coll

6

1 reference

22 September 2017

Ricardo Correa-Rotter

7

1 reference

22 September 2017

Fan Fan Hou

8

1 reference

22 September 2017

Donald Kohan

9

1 reference

22 September 2017

Hirofumi Makino

11

1 reference

22 September 2017

Hans-Henrik Parving

12

1 reference

22 September 2017

Vlado Perkovic

13

1 reference

22 September 2017

Robert Toto

16

1 reference

22 September 2017

Jarno Hoekman

17

1 reference

22 September 2017

Hiddo J Lambers Heerspink

18

1 reference

22 September 2017

publication date

30 July 2015

1 reference

European Journal of Preventive Cardiology

22 September 2017

published in

1 reference

22 September 2017

volume

23

1 reference

22 September 2017

issue

7

1 reference

22 September 2017

page(s)

758-768

1 reference

The kidney in type 2 diabetes therapy

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F2047487315598709

Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487315598709

Endothelin and endothelin antagonists in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487315598709

Endothelin antagonists in diabetic nephropathy: back to basics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487315598709

Avosentan reduces albumin excretion in diabetics with macroalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487315598709

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487315598709

Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487315598709

The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487315598709

Avosentan for overt diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487315598709

Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487315598709

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487315598709

The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487315598709

Comparison of different measures of urinary protein excretion for prediction of renal events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487315598709

Predictors of congestive heart failure after treatment with an endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487315598709

Enrichment of clinical study populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487315598709

Risk prediction models: II. External validation, model updating, and impact assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487315598709

Pharmacology: defining the optimal dose of a new drug: a crucial decision

21 January 2018

1 reference

12 December 2020

Endothelin antagonists for diabetic and non-diabetic chronic kidney disease

1 reference

12 December 2020

Changes in diabetes-related complications in the United States, 1990-2010

1 reference

12 December 2020

A novel approach for establishing cardiovascular drug efficacy

1 reference

12 December 2020

The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers

1 reference

12 December 2020

Identifiers

DOI

10.1177/2047487315598709

1 reference

22 September 2017

1 reference